Lipoxygenase pathway receptor expression in ovarian cancer

Academic Article

Abstract

  • Objective: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy. Study design: Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). Results: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P =.05), suboptimal debulking (P =.07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. Conclusions: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted. © 2008 by the Society for Gynecologic Investigation.
  • Digital Object Identifier (doi)

    Author List

  • Rocconi RP; Kirby TO; Seitz RS; Beck R; Straughn JM; Alvarez RD; Huh WK
  • Start Page

  • 321
  • End Page

  • 326
  • Volume

  • 15
  • Issue

  • 3